Stock Track | I-MAB (IMAB) Soars 6.19% on Positive Analyst Ratings and Upcoming Investor Conferences

Stock Track

Aug 21, 2025

Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company, surged 6.19% during intraday trading on Thursday. The significant uptick comes on the heels of positive analyst ratings and the company's announcement of its participation in upcoming investor conferences.

HC Wainwright & Co. reaffirmed their confidence in I-MAB by maintaining their price target at $7.00 per share. Additionally, Needham reiterated their "Buy" rating for the company. These positive assessments from reputable financial firms likely contributed to the increased investor interest and subsequent stock price rally.

Further boosting market sentiment, I-MAB revealed its plans to participate in two major investor conferences in September. The company will attend the Cantor Global Healthcare Conference from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference on September 10. These events provide I-MAB with valuable opportunities to showcase its pipeline, particularly its lead candidate givastomig, a potential best-in-class bispecific antibody for gastric cancer treatment. The prospect of increased visibility among investors and potential partnerships could be driving the stock's upward movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1193060018"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193060018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193060018?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193060018","market":"nz","top_or_hot":-1,"title":"Stock Track | I-MAB (IMAB) Soars 6.19% on Positive Analyst Ratings and Upcoming Investor Conferences","media":"Stock Track","content":"<p>Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company, surged 6.19% during intraday trading on Thursday. The significant uptick comes on the heels of positive analyst ratings and the company's announcement of its participation in upcoming investor conferences.</p>\n\n<p>HC Wainwright & Co. reaffirmed their confidence in I-MAB by maintaining their price target at $7.00 per share. Additionally, Needham reiterated their \"Buy\" rating for the company. These positive assessments from reputable financial firms likely contributed to the increased investor interest and subsequent stock price rally.</p>\n\n<p>Further boosting market sentiment, I-MAB revealed its plans to participate in two major investor conferences in September. The company will attend the Cantor Global Healthcare Conference from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference on September 10. These events provide I-MAB with valuable opportunities to showcase its pipeline, particularly its lead candidate givastomig, a potential best-in-class bispecific antibody for gastric cancer treatment. The prospect of increased visibility among investors and potential partnerships could be driving the stock's upward movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | I-MAB (IMAB) Soars 6.19% on Positive Analyst Ratings and Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | I-MAB (IMAB) Soars 6.19% on Positive Analyst Ratings and Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-21 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company, surged 6.19% during intraday trading on Thursday. The significant uptick comes on the heels of positive analyst ratings and the company's announcement of its participation in upcoming investor conferences.</p>\n\n<p>HC Wainwright & Co. reaffirmed their confidence in I-MAB by maintaining their price target at $7.00 per share. Additionally, Needham reiterated their \"Buy\" rating for the company. These positive assessments from reputable financial firms likely contributed to the increased investor interest and subsequent stock price rally.</p>\n\n<p>Further boosting market sentiment, I-MAB revealed its plans to participate in two major investor conferences in September. The company will attend the Cantor Global Healthcare Conference from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference on September 10. These events provide I-MAB with valuable opportunities to showcase its pipeline, particularly its lead candidate givastomig, a potential best-in-class bispecific antibody for gastric cancer treatment. The prospect of increased visibility among investors and potential partnerships could be driving the stock's upward movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1193060018","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193060018","pubTimestamp":1755786025,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company, surged 6.19% during intraday trading on Thursday. The significant uptick comes on the heels of positive analyst ratings and the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"个股追踪|天境生物(IMAB)因积极的分析师评级和即将举行的投资者会议而飙升6.19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMAB":1},"content_text":"Shares of I-MAB (NASDAQ: IMAB), a U.S.-based global biotech company, surged 6.19% during intraday trading on Thursday. The significant uptick comes on the heels of positive analyst ratings and the company's announcement of its participation in upcoming investor conferences.\nHC Wainwright & Co. reaffirmed their confidence in I-MAB by maintaining their price target at $7.00 per share. Additionally, Needham reiterated their \"Buy\" rating for the company. These positive assessments from reputable financial firms likely contributed to the increased investor interest and subsequent stock price rally.\nFurther boosting market sentiment, I-MAB revealed its plans to participate in two major investor conferences in September. The company will attend the Cantor Global Healthcare Conference from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference on September 10. These events provide I-MAB with valuable opportunities to showcase its pipeline, particularly its lead candidate givastomig, a potential best-in-class bispecific antibody for gastric cancer treatment. The prospect of increased visibility among investors and potential partnerships could be driving the stock's upward movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}